Cue Biopharma (CUE) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Cue Biopharma (CUE) over the last 5 years, with Q3 2025 value amounting to -$0.07.
- Cue Biopharma's EPS (Weighted Average and Diluted) rose 5882.35% to -$0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.43, marking a year-over-year increase of 5274.73%. This contributed to the annual value of -$0.71 for FY2024, which is 3622.02% up from last year.
- Cue Biopharma's EPS (Weighted Average and Diluted) amounted to -$0.07 in Q3 2025, which was up 5882.35% from -$0.09 recorded in Q2 2025.
- Cue Biopharma's EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.07 during Q3 2025, with a 5-year trough of -$0.44 in Q1 2022.
- In the last 5 years, Cue Biopharma's EPS (Weighted Average and Diluted) had a median value of -$0.25 in 2021 and averaged -$0.26.
- As far as peak fluctuations go, Cue Biopharma's EPS (Weighted Average and Diluted) tumbled by 5971.22% in 2022, and later surged by 5882.35% in 2025.
- Cue Biopharma's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.25 in 2021, then plummeted by 59.71% to -$0.4 in 2022, then rose by 27.37% to -$0.29 in 2023, then skyrocketed by 42.8% to -$0.17 in 2024, then surged by 57.8% to -$0.07 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.07 for Q3 2025, versus -$0.09 for Q2 2025 and -$0.17 for Q1 2025.